On part two of this episode series, hosts Michael Beasley, MD and Priya Umapathi, MD continue their discussion on the top highlights of 2022 with current HFSA president Dr. John Teerlink. The STRONG-HF clinical trial, the future of Omecamtiv Mecarbil and the METEORIC-HF trial are discussed. Priya introduces her new episode segment "From Failure to Function," which summarizes the latest heart failure research presented at meetings around the world.